FDA delays Thrombin review

08/23/2007 | SeattlePI.com

The FDA has postponed completing a review of ZymoGenetics' blood-clotting drug Thrombin so it can further examine manufacturing data, the company announced. The review now is expected to be completed by Jan. 17 of next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC